Semaglutide, a Once-Weekly Human GLP-1 Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/Levonorgestrel

Lignende værker

• A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
  af: Ikushima, Ippei, et al.
  Udgivet: (2018)
• Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives
  af: Benagiano, Giuseppe, et al.
  Udgivet: (2009)
• Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women
  af: Edelman, Alison, et al.
  Udgivet: (2012)
• Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal women
  af: Frey, Reiner, et al.
  Udgivet: (2016)
• The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
  af: Rasmussen, Mads Frederik
  Udgivet: (2020)